[Chemoradiation in bladder cancer].
Bladder cancer is the second most common urologic tumor after prostate cancer. Radical cystectomy is the standard treatment of localized muscle-invasive tumors. However, urinary diversion (using a conduit or continent diversion) following radical cystectomy can be debilitating. Moreover, delayed metastases appear frequently in spite of radical surgery. So, for selected patients, chemoradiotherapy is a valid therapeutic alternative to cystectomy. Cisplatin or derivatives are administered concurrently to radiation therapy up to 60-65 Gy. Patients undergo control cystoscopy at mid-course in treatment in order to select responders from non responders. This review summarizes the main published series of radiochemotherapy in invasive bladder cancer. Results for local control, survivals, bladder preservation rates and toxicity are presented.
Hôpital Européen Georges-Pompidou, Service d'onco-radiothérapie, AP-HP, 20, rue Leblanc, 75015 Paris, France. martin.housset@egp.aphp.fr <martin.housset@egp.aphp.fr>
M
M
Housset
C
C
Durdux
J
J
Thariat
B
B
Dufour
D003131:Combined Modality Therapy; D006801:Humans; D009361:Neoplasm Invasiveness; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*